Search our team at AdventHealth Research Institute
-
NCT05563220
STML-ELA-022 A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer (ELEVATE)
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Cancer ResearchResearch Location: Altamonte, FloridaThis research study is being done to find out if elacestrant is safe and tolerable when given in combination with one of the following study drugs, approved in the treatment of advanced breast cancer...
-
NCT05865535
AV-380-22-102: A Phase 1 Dose Escalation Study of AV-380 in Combination with Standard of Care Chemotherapy in Metastatic Cancer Patients with Cachexia and Elevated GDF-15 Levels
This study is currently enrolling.Research Area: Cancer ResearchResearch Location: Orlando, FloridaThe study involves research. The purpose of the study is to see if a single dose and multiple doses of the study drug, AV 380, are safe and tolerated in cancer participants. This study will also help...
-
NCT04956640
LOXO-RAS-20001: A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors
This study is currently enrolling.Research Area: Cancer ResearchResearch Location: Orlando, FloridaThe main purpose of this research study (during both monotherapy and combination therapy evaluation) includes the following: To determine whether LY3537982 is safe; To identify which dose level of...
-
NCT04427384
A Multicenter Observational Study of GammaTile™ Surgically Targeted Radiation Therapy (STaRT) in Intracranial Brain Neoplasms
This study is currently enrolling.Associated Conditions: Brain CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this research is to evaluate real-world clinical outcomes and patient-reported
outcomes that measure the effectiveness and safety of GammaTiles, which is the type of
radiation therapy... -
NCT05346835
68284528MMY4006 EAP: Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma
This study is currently enrolling.Associated Conditions: Multiple MyelomaResearch Area: Cancer ResearchResearch Location: Orlando, Florida -
NCT05948865
CPO301-US-101: A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients with Advanced or Metastatic Solid Tumors
This study is currently enrolling.Associated Conditions: Multiple MyelomaResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe purpose of the study, called CPO301-US-101, is to see if CPO301 (also known as SYS6010) is safe and effective in treating your type of cancer when administered as an intravenous (administered into...
-
NCT05822752
M24-147: A Phase 2, Randomized Open-Label Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab for locally advanced or Metastatic Hepatocellular Carcinoma (HCC) patients who have progressed after an approved immune checkpoint inhibitor containing regimen in 1L HCC
This study is currently enrolling.Associated Conditions: Liver CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to determine the optimal dose of livmoniplimab and to determine if livmoniplimab in combination with budigalimab is safe and effective at treating locally advanced or...
-
NCT04083599
GCT1042-01: A First-in-Human, Open-label, Dose-escalation Trial with Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects with Malignant Solid Tumors
This study is currently enrolling.Associated Conditions: Malignant Pleural MesotheliomaResearch Area: Cancer ResearchResearch Location: Orlando, FloridaGEN1042 is a bispecific antibody that crosslinks CD40 on antigen-presenting cells with 4-1BB on activated T cells, thereby inducing conditional stimulation of and co-stimulatory activity on both cell...
-
NCT04416984
ALLO-501A-201: A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B Cell Lymphoma (LBCL). (Alpha2 Study)
This study is currently enrolling.Associated Conditions: LymphomaResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThere are 2 unapproved agents being evaluated in this study: ALLO-501A, and ALLO-647, which are used together and are being evaluated as a treatment for lymphoma. ALLO-647 is an antibody that will...
-
NCT05639751
PRT3789-01: A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 in Participants with Select Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
This study is currently enrolling.Associated Conditions: Lung CancerResearch Area: Cancer ResearchResearch Location: Celebration, FloridaThe purpose of this research study is to test the safety of PRT3789 at different dose levels to find out what effects, good and/or bad, PRT3789 has on you and your type of cancer. The information...
-
NCT04637763
CB-010: A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
This study is currently enrolling.Research Area: Cancer ResearchResearch Location: Orlando, FloridaAllogeneic CAR-T cell therapy is a type of cancer therapy in which a healthy donor’s T cells (a type of immune system cell that circulates in blood) are modified during manufacturing using CRISPR...
-
Childhood Sjogren Disease Long Term Outcomes
This study is currently enrolling.Research Area: Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this research is to describe the natural history of children diagnosed with, or suspected of being at risk for development of, childhood Sjogren Disease. This is a critically...